News

< Back

AFAR in the News: Tech Times on Promising TAME Trial

On August 26, 2015, Tech Times spotlighted AFAR’s role in facilitating the planning process for the Taming Aging with Metformin (TAME) trial. The article also included insights from the trial’s lead investigator and AFAR Deputy Scientific Director, Nir Barzilai, MD; Board Member James Kirkland, MD, PhD; and grantee Brian Kennedy, PhD.

This feature discussed both the clinical design and the projected goals of the TAME trial. As Dr. Barzilai stated, “The number one purpose is the idea that we have a drug that we can use in humans that can delay or prevent aging. But the second goal, which is in a way more important if the study works, is to convince the FDA that aging can be a target.”

Researchers believe that by creating an indication for “comorbidities of aging” both personal healthcare costs, related to treatment of end of life diseases and disabilities, and pharmaceutical research costs, related to treating one disease at a time, will decrease.

Read the complete article here and check out other recent pieces on the TAME trial here, here, or here.

Nir Barzilai, MD, is the Director of the Institute for Aging Research at Albert Einstein College of Medicine and a two-time AFAR grant recipient.

Brian Kennedy, PhD, is the President and CEO of the Buck Institute for Research on Aging and the recipient of a 2003 AFAR Research Award and 2008 Julie Martin Mid-Career Award in Aging Research.

James Kirkland, MD, PhD, is the director of the Robert and Arlene Kogod Center on Aging at the Mayo Clinic and the 2012 recipient of a Glenn/AFAR Breakthroughs in Gerontology Award.

More Recent News

View All News >
Encouraged by AFAR Amplifying Geroscience Initiative, Congress is directing NIH to tabulate annual spending on geroscience research.
Encouraged by AFAR Amplifying Geroscience Initiative, Congress is directing NIH to tabulate annual spending on geroscience research.
Grantee News: 2022 McKnight Brain Research Foundation Innovator Awards in Cognitive Aging and Memory Loss recipient Tara Tracy, PhD featured as one “next generation of biotech superstars”; publishes research on new strategies for addressing Alzheimer’s and dementia-related memory problems
Grantee News: 2022 McKnight Brain Research Foundation Innovator Awards in Cognitive Aging and Memory Loss recipient Tara Tracy, PhD featured as one “next generation of biotech superstars”; publishes research on new strategies for addressing Alzheimer’s and dementia-related memory problems
AFAR Grantee in the News: New Research by Ömer Yilmaz on the SOX 17 gene and its contributions to Colon cancer detection was published in Nature.
AFAR Grantee in the News: New Research by Ömer Yilmaz on the SOX 17 gene and its contributions to Colon cancer detection was published in Nature.
In Memoriam: Marc Weksler, MD, former AFAR Board President
In Memoriam: Marc Weksler, MD, former AFAR Board President
In Memoriam: Norman Volk, Former AFAR Board Member
In Memoriam: Norman Volk, Former AFAR Board Member
AFAR Grantee in the News: New Research by AFAR Grantee Aditi Gurkar on the molecular index of biological aging published in Aging Cell.
AFAR Grantee in the News: New Research by AFAR Grantee Aditi Gurkar on the molecular index of biological aging published in Aging Cell.
AFAR Grantee in the News: New Research by Dibyadeep Datta on a biomarker that could indicate ensuing Alzheimer's disease published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
AFAR Grantee in the News: New Research by Dibyadeep Datta on a biomarker that could indicate ensuing Alzheimer's disease published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
AFAR Grantee in the News: New Research by Mark E. Kleinman on histone dynamics, cellular senescence, and aging in Aging Cell.
AFAR Grantee in the News: New Research by Mark E. Kleinman on histone dynamics, cellular senescence, and aging in Aging Cell.
AFAR News: Gareth W. Shepherd, PhD, and Robert W. Stearns elected to Board of Directors
AFAR News: Gareth W. Shepherd, PhD, and Robert W. Stearns elected to Board of Directors